Frontier Bio

Frontier Bio is a pioneering company in the field of tissue engineering, focused on revolutionizing medical device testing and therapeutics development. Their groundbreaking technology involves creating lab-grown human blood vessels using a biodegradable polymer scaffold seeded with vascular cells and cultivated under biomimetic conditions. Frontier Bio's innovative manufacturing methods leverage 3D printing to produce these vessels in various complex shapes, mimicking natural vascular architecture and even disease states like aneurysms.

In a proof-of-concept study conducted in collaboration with Mayo Clinic in October 2023, Frontier Bio successfully created a tissue-engineered blood vessel with an aneurysm and deployed a vascular flow diverter device into it. These devices are commonly used to direct blood flow away from aneurysms, reducing the risk of further expansion or rupture. The cell growth across the flow diverter was assessed, and the results were comparable to those observed in established animal studies conducted on rabbits.

This revolutionary approach to medical device testing aligns with evolving global ethical standards and ensures higher accuracy and precision due to the use of human cells. It enables immediate impacts on the medical field, ensuring safer and more reliable testing outcomes. Frontier Bio's research has been supported by the highly competitive National Science Foundation (NSF) Small Business Innovation Research (SBIR) program, which funds early-stage, high-impact concepts and stimulates technological innovation.

In addition to blood vessels, Frontier Bio's pioneering efforts extend to the development of neural and lung tissues. The company's long-term vision is to create engineered tissues that can transform medicine, eliminating the need for organ donations.